Cargando…

97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience

Detalles Bibliográficos
Autores principales: Angelis, V., McFarlane, P., Cunningham, N., Gennatas, S., Johnston, S.R.D., Okines, A., McGrath, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society for Medical Oncology. Published by Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106264/
http://dx.doi.org/10.1016/j.annonc.2021.03.111
_version_ 1783689749648637952
author Angelis, V.
McFarlane, P.
Cunningham, N.
Gennatas, S.
Johnston, S.R.D.
Okines, A.
McGrath, S.
author_facet Angelis, V.
McFarlane, P.
Cunningham, N.
Gennatas, S.
Johnston, S.R.D.
Okines, A.
McGrath, S.
author_sort Angelis, V.
collection PubMed
description
format Online
Article
Text
id pubmed-8106264
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher European Society for Medical Oncology. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-81062642021-05-10 97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience Angelis, V. McFarlane, P. Cunningham, N. Gennatas, S. Johnston, S.R.D. Okines, A. McGrath, S. Ann Oncol Article European Society for Medical Oncology. Published by Elsevier Ltd. 2021-05 2021-05-08 /pmc/articles/PMC8106264/ http://dx.doi.org/10.1016/j.annonc.2021.03.111 Text en Copyright © 2021 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Angelis, V.
McFarlane, P.
Cunningham, N.
Gennatas, S.
Johnston, S.R.D.
Okines, A.
McGrath, S.
97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience
title 97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience
title_full 97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience
title_fullStr 97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience
title_full_unstemmed 97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience
title_short 97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience
title_sort 97p is continuing cdk4-6 inhibitor therapy safe during the covid-19 pandemic? a uk cancer centre experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106264/
http://dx.doi.org/10.1016/j.annonc.2021.03.111
work_keys_str_mv AT angelisv 97piscontinuingcdk46inhibitortherapysafeduringthecovid19pandemicaukcancercentreexperience
AT mcfarlanep 97piscontinuingcdk46inhibitortherapysafeduringthecovid19pandemicaukcancercentreexperience
AT cunninghamn 97piscontinuingcdk46inhibitortherapysafeduringthecovid19pandemicaukcancercentreexperience
AT gennatass 97piscontinuingcdk46inhibitortherapysafeduringthecovid19pandemicaukcancercentreexperience
AT johnstonsrd 97piscontinuingcdk46inhibitortherapysafeduringthecovid19pandemicaukcancercentreexperience
AT okinesa 97piscontinuingcdk46inhibitortherapysafeduringthecovid19pandemicaukcancercentreexperience
AT mcgraths 97piscontinuingcdk46inhibitortherapysafeduringthecovid19pandemicaukcancercentreexperience